PDF(Pubmed)
Abstract：
In a retrospective view, this review examines the impact of mucormycosis on health workers and researchers during the COVID era. The diagnostic and treatment challenges arising from unestablished underlying pathology and limited case studies add strain to healthcare systems. Mucormycosis, caused by environmental molds, poses a significant threat to COVID-19 patients, particularly those with comorbidities and compromised immune systems. Due to a variety of infectious Mucorales causes and regionally related risk factors, the disease\'s incidence is rising globally. Data on mucormycosis remains scarce in many countries, highlighting the urgent need for more extensive research on its epidemiology and prevalence. This review explores the associations between COVID-19 disease and mucormycosis pathology, shedding light on potential future diagnostic techniques based on the fungal agent\'s biochemical components. Medications used in ICUs and for life support in ventilated patients have been reported, revealing the challenge of managing this dual onslaught. To develop more effective treatment strategies, it is crucial to identify novel pharmacological targets through \"pragmatic\" multicenter trials and registries. In the absence of positive mycology culture data, early clinical detection, prompt treatment, and tissue biopsy are essential to confirm the specific morphologic features of the fungal agent. This review delves into the history, pathogens, and pathogenesis of mucormycosis, its opportunistic nature in COVID or immunocompromised individuals, and the latest advancements in therapeutics. Additionally, it offers a forward-looking perspective on potential pharmacological targets for future drug development.
摘要：
在回顾视图中，这篇综述研究了COVID时代毛霉菌病对卫生工作者和研究人员的影响。由未确定的潜在病理学和有限的案例研究引起的诊断和治疗挑战增加了医疗保健系统的压力。毛霉菌病,由环境霉菌引起的，对COVID-19患者构成重大威胁，特别是那些有合并症和免疫系统受损的人。由于各种传染性毛霉病的原因和区域相关的危险因素，这种疾病的发病率正在全球上升。在许多国家，毛霉菌病的数据仍然很少，强调迫切需要对其流行病学和流行进行更广泛的研究。这篇综述探讨了COVID-19疾病与毛霉菌病病理之间的关系，基于真菌剂生化成分的潜在未来诊断技术。据报道，ICU中使用的药物和通气患者的生命支持，揭示了管理这种双重冲击的挑战。为了制定更有效的治疗策略，通过“务实”多中心试验和登记处确定新的药理靶点至关重要。在没有阳性真菌学培养数据的情况下，早期临床检测，及时治疗,和组织活检对于确认真菌剂的特定形态特征至关重要。这篇评论深入研究了历史，病原体,和毛霉菌病的发病机理，其在COVID或免疫受损个体中的机会主义性质，以及治疗学的最新进展。此外,它为未来药物开发的潜在药理靶点提供了前瞻性观点.
